Terminal differentiation in a non-small-cell bronchopulmonary carcinoma correlates with increased expression of p53

Anticancer Research

Volumn 16, Issue 3 A, 1996, Pages 1209-1212

  Liscia, E ^a   Riou, D ^b   Siavoshian, S ^a   Boesch, S ^a   Lebert, V ^a   Tomasoni, C ^a   Dabouis, G ^b   Biard, J F ^a   Roussakis, C ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Anti oncogenes; Differentiation inducers; Non small cell lung carcinoma; Oncogenes; Terminal differentiation

Indexed keywords

ANTINEOPLASTIC AGENT; BISTRAMIDE D; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE C ERB; ONCOGENE MYC; ONCOGENE RAS; ONCOGENE SRC; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; BRONCHIAL NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; ETHERS, CYCLIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029957807     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Walling J: Chemotherapy for advanced non-small-cell lung cancer. Respiratory Medicine 88. 649-657, 1994.
2. Sachs L: Cell Differentiation and bypassing of genetic defects in the suppression of malignancy Cancer Res 47: 1981-1986, 1987.
3. Barry Pierce G and Speers W C Tumors as caricatures of the process of tissue renewal, prospects for therapy by directing differentiation. Cancer Res 46. 1996-2004, 1988.
4. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L: All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 76: 1704-1709, 1990.
5. Riou D, Roussakis C, Robillard N, Biard JF and Verbist JF: Comparative study of the antitumoral activity of bistramides A, D and K towards a non-small-cell bronchopulmonary carcinoma. Anticancer Res 13: 2331-2334, 1993.
6. Riou D, Roussakis C, Robillard N, Biard JF and Verbist JF: Bistramide A-induced irreversible arrest of cell proliferation m a nonsmall-cell bronchopulmonary carcinoma is similar to induction of terminal maturation. Biol Cell 77: 261-264, 1993.
7. Roussakis C, Charrier J, Riou D, Biard JF, Malochet C, Meflah K and Verbist JF: Chemotherapeutic inhibition of erbB2 oncogene expression on a non-small-cell cancer line (NSCLC-N6). Anti-Cancer Drug Design 9: 119-123, 1994.
8. Kern JA, Schwartz DA, Nordberg EN, Weiner DB, Greene MI, Torney I and Robinson RA: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5191, 1990.
9. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao X, Fang K and Roth JA: Differential expression of the c-erb-B2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968-4971, 1989.
10. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL and Hung MC: Gerb-B2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266, 1994.
11. Kiefer PE, Wegmann B, Bacher M, Erbil C, Heidtmann H and Havemann K. different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines. J Cancer Res Clin Oncol 116: 29-37, 1990.
12. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52: 4799-4804, 1992.
13. Sundaresan V, Ganly P, Hasleston P, Rudd R, Sinha G, Bleehen NM and Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989-1997, 1992.
14. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85: 2018-2023, 1993.
15. Biedler JL, Spengler BA and Ross RA: Cellular maturation and oncogene expression during drug-induced differentiation in vitro: a brief review. In: Effects of therapy on biology and kinetics of the residual tumor, part A: pre-clinical aspects, 287-312, Wiley-Liss ed, 1990.
16. Liebermann DA and Hoffman B: Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation. Stem Cells 12. 352-369, 1994.
17. Roussakis C, Gratas C, Audoin AF, Le Boterff J, Dabouis G, Andre MJ. Moyon E, Vo NH. Pradal G and Verbist JF: Study of in vitro sensitivity of a newly established cell Sine from a primary bronchial epidermoid carcinoma of human origin (NSCLCN). Anticancer Res 11: 2239-2244, 1991.
18. Gouiffes D, Juge M, Grimaud N, Welin L, Sauviat MP, Barbin V, Laurent D. Roussakis C, Henichart JP and Verbist JF: Bistramide A, a new toxin from the Urochordata Lissoclinum bistratum Sluitter: isolation and preliminary characterisation. Toxicon 26. 1129-1136, 1988.
19. Foster MP, Mayne CL, Dunkel R, Pugmire RJ, Grant DM, Kornprobst JM, Verbist JF, Biard JF and Ireland CM: The revised structure of bistramide A (bistratene): application of a new program for the automated analysis of 2D INADEQUATE spectra. J Am Chem Soc 114: 1110-1111, 1992.
20. Chirgwin JM, Przybyla AE, Macdonald RJ and Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 19: 5294-5299, 1979.
21. Gusterson BA: Identification and interpretation of epidermal growth factor and c-erb-B2 overexpression. Eur J Cancer 28: 263-267,1992.
22. Schlechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984.
23. Veale D, Kerr N, Gibson GJ and Harris AL: Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res 49: 1313-1317, 1989.
24. Veale D, Ashcroft T, Marsh C, Gibson GJ and Harris AL: Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55: 513-516, 1987.
25. Gullick WJ, Berger MS, Bennett PLP, Rothbard JB and Waterfield MD: Expression of the c-erb-B2 protein in normal and transformad cells. Int J Cancer 40: 246-254, 1987.
26. Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D and Lippman ME: Direct interaction of a ligand for the erb-R2 oncogene product with the EGF receptor and p185erhB2. Science 249: 1552-1555, 1990.
27. Peles E and Yarden Y: Neu and its ligands: from an oncogene to neural factors . Bioessays 15: 814-825, 1993.
28. Carpenter G and Cohen S: Epidermal growth factor. Annu Rev Biochem 48: 193-216, 1979.
29. Prins J, De Vries EGE and Mulder NH: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Auticancer Res 13: 1373-1386, 1993.
30. Gomez-Casares MT, Delgado MD, Lerga A, Crespo P, Quincoees AF, Richard C and Leon J: Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells. Leukemia 7: 1824-1833, 1993.
31. Schaefer A, Dressel A, Lingelbach K, Schmidt CA, Steinheider G and Marquardt H. Induction of differentiation in Frienderythroleukemia cells by aclacynomycin A: early transient decrease in c-myc and c-myb mRNA levels. Leukemia 6: 823-833, 1992.
32. Lachman HM: C-myc protooncogene expression in mouse erythroleukemia cells. Environ Health Perspect 80: 161-172, 1989.
33. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
34. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
35. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependant apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.